The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase

Onkologie

Volumn 31, Issue 11, 2008, Pages 585-589

  Li, Jian Yong ^a   Xu, Wei ^a   Wu, Wei ^a   Zhu, Yu ^a   Qiu, Hai Rong ^a   Zhang, Run ^a   Zhang, Su Jiang ^a   Qian, Si Xuan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic myeloid leukemia; Derivative chromosome 9; Fluorescence in situ hybridization

Indexed keywords

BCR ABL PROTEIN; HYDROXYUREA; IMATINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BONE MARROW CELL; CANCER GROWTH; CANCER INCIDENCE; CHROMOSOMAL INSTABILITY; CHROMOSOME DELETION; CHROMOSOME DELETION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPING; LYMPHOID CELL; MALE; PROGNOSIS;

ADOLESCENT; ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58849140504     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000160578     Document Type: Article

References (20)

1. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, et al.: Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-280.
2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM: The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.
3. Sinclair PB, Green AR, Grace C, Nacheva EP: Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997;90:1395-1402.
4. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B, Green AR: Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000;95:738-743.
5. Herens C, Tassin F, Lemaire V, Beguin Y, Collard E, Lampertz S, Croisiau C, Lecomte M, De Prijk B, Longree L, Koulischer L: Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 2000;110:214-216.
6. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR: Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001;98:1732-1738.
7. Huntly BJ, Bench A, Green AR: Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003;102:1160-1168.
8. Fourouclas N, Campbell PJ, Bench AJ, Swanton S, Baxter EJ, Huntly BJ, Green AR: Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia. Haematologica 2006;91:952-955.
9. Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, Reiter A, Hochhaus A, Cross NC; German Chronic Myelogenous Leukemia (CML) Study Group: Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007;110:1283-1290.
10. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, et al.: Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984;63:789-799.
11. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-858.
12. Storlazzi CT, Specchia G, Anelli L, Albano F, Pastore D, Zagaria A, Rocchi M, Liso V: Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 2002;35:271-276.
13. Mitelman F (ed): ISCN: An International System for Human Cytogenetic Nomenclature. Basel, S. Karger, 1995.
14. Specchia G, Albano F, Anelli L, Storlazzi CT, Zagaria A, Liso A, Pannunzio A, Pastore D, Mestice A, Greco G, Liso V, Rocchi M: Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes. Leuk Lymphoma 2004;45:689-694.
15. Douet-Guilbert N, Morel F, Quemener S, Maguer A, Le Bris MJ, Morice P, Berthou C, De Braekeleer M: Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia. Cancer Genet Cytogenet 2006;170:89-92.
16. Birney E, Bateman A, Clamp ME, Hubbard TJ: Mining the draft human genome. Nature 2001;409:827-828.
17. Lundan T, Volin L, Ruutu T, Knuutila S, Porkka K: Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9. Leukemia 2005;19:138-140.
18. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE: Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004;125:187-195.
19. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, Byrne J, Brizard A, Niederwieser D, Freeman-Edward J, Cuthbert G, Bown N, Clark RE, Nacheva EP, Green AR, Deininger MW: Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003;102:2205-2212.
20. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J: Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105:2281-2286.